Concord Drugs approves FY26 financials, sets September 30 AGM date
- Concord Drugs board approved audited standalone and consolidated financial statements for FY26
- The 31st Annual General Meeting is scheduled for September 30, 2026 via video conference
- Record date for remote e-voting eligibility is set as September 23, 2026
- S. Nagi Reddy proposed for re-appointment as Chairman and Managing Director
*this image is generated using AI for illustrative purposes only.
Concord Drugs board approved the company’s audited standalone and consolidated financial statements for FY26 during a meeting held on September 7, 2026. The directors also approved the notice for the 31st Annual General Meeting (AGM), scheduled to take place via video conferencing on September 30, 2026.
The board set the record date for remote e-voting eligibility as September 23, 2026. The register of members and share transfer books will remain closed from September 24 to September 30, 2026, both days inclusive.
Governance and Appointments
The board proposed the re-appointment of S. Nagi Reddy, Chairman and Managing Director, who retires by rotation at the ensuing AGM. Reddy holds 30,60,536 equity shares in the company and has approximately 28 years of experience in the pharmaceutical industry.
Two independent directors were also recommended for re-appointment for second terms of five consecutive years:
- S. Nagavenkata Hareesh Kumar Solleti, subject to member approval
- Sumeela Kasu, with a term commencing June 1, 2027, to May 31, 2032
Auditor and Transaction Approvals
Based on the Audit Committee’s recommendation, the board approved the re-appointment of Pundarikashyam and Associates as statutory auditors for five consecutive years. The proposed remuneration is ₹4,00,000 per annum, plus applicable taxes and reimbursement of reasonable out-of-pocket expenses.
The board also sought member approval for material related-party transactions proposed for FY27, stating these would be undertaken in the ordinary course of business on an arm’s-length basis. Additionally, the remuneration of KJU & Associates, appointed as cost auditors for FY27, requires ratification by members.
What the Numbers Show
The filing focuses on procedural governance rather than operational performance metrics. With no revenue, profit, or order inflow data disclosed in this specific board outcome notice, the primary signal is continuity in leadership and audit oversight, ensuring stability in corporate governance for the upcoming fiscal year.
Historical Stock Returns for Concord Drugs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.39% | -1.76% | +11.89% | +10.68% | +24.53% | 0.0% |
How will the re-appointment of Chairman S. Nagi Reddy influence Concord Drugs' strategic direction and market positioning in FY27?
What specific operational or financial metrics are investors anticipating in the upcoming standalone and consolidated financial statements for FY26?
Could the approval of material related-party transactions for FY27 signal any changes in supply chain dependencies or internal cost structures?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
